Good Life Advisers LLC boasted its position in shares of Finer And. (NYSE:PFE – Free Report) by 27.1% during the th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,410 shares of the biopharmaceutical company’s stock after acquiring an additional 15,211 shares during the quarter. Good Life Advisers LLC’s holdings in Finer were worth $1,895,000 at the end of the most recent reporting period. Met Finer alert: Sign Up
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Swiss National Bank raised its position in shares of Finer by 0.6% in the third quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company’s stock valued at $486,762,000 after purchasing an additional 100,900 shares during the period. Charles Schwa Investment Management And. grew its stake in shares of Finer by 11.0% in the third quarter. Charles Schwa Investment Management And. now owns 130,143,942 shares of the biopharmaceutical company’s stock valued at $3,766,366,000 after acquiring an additional 12,864,343 shares in the last quarter. Empowered Funds LLC grew its stake in shares of Finer by 80.9% in the third quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company’s stock valued at $14,709,000 after acquiring an additional 227,349 shares in the last quarter. Addison Advisers LLC grew its stake in shares of Finer by 394.2% in the third quarter. Addison Advisers LLC now owns 52,238 shares of the biopharmaceutical company’s stock valued at $1,512,000 after acquiring an additional 41,668 shares in the last quarter. Finally, KBC Group of grew its stake in shares of Finer by 26.0% in the third quarter. KBC Group of now owns 3,105,433 shares of the biopharmaceutical company’s stock valued at $89,872,000 after acquiring an additional 639,985 shares in the last quarter. 68.36% of the stock is owned by institutional investors. Analyst Eating Changes
Several equities analysis recently commented on PFE shares. Citigroup decreased their price target on shares of Finer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January with. Wrist Financial reduced their price objective on shares of Finer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December with. Bank of America reiterated a “neutral” rating and set a $29.00 price objective on shares of Finer in a research note on Tuesday, December with. Wolfe Research started coverage on shares of Finer in a research note on Friday, November with. They set an “underperform” rating and a $25.00 price objective on the stock. Finally, Guggenheim reiterated a “buy” rating and set a $33.00 price objective on shares of Finer in a research note on Monday, February with. One equities research analyst has rate the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92. View Our Latest Stock Analysis on PFE
Insider Activity at Finer
In other Finer news, Director Donald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February with. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. His represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC webster. 0.06% of the stock is owned by company insider. Finer Trading Up 0.1 %
PFE opened at $25.56 on Wednesday. The company’s 50 day moving average is $26.26 and its 200-day moving average is $27.46. Finer And. has a 1-year low of $24.48 and a 1-year high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market cap of $144.82 billion, a P/E ratio of 18.12, a PEG ratio of 0.63 and a beta of 0.64. Finer (NYSE:PFE – Met Free Report) last posted its quarterly earnings results on Tuesday, February th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysis’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Finer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period last year, the company posted $0.10 EPS. Equities research analysis predict that Finer And. will post 2.95 earnings per share for the current fiscal year. Finer Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March th. Investors of record on Friday, January with will be issued a $0.43 dividend. His represents a $1.72 dividend on an annualized basis and a yield of 6.73%. The ex-dividend date of this dividend is Friday, January with. His is a positive change from Finer’s previous quarterly dividend of $0.42. Finer’s dividend layout ratio (DPR) is 121.99%. Finer Company Profile
Finer And discovers, develops, manufactures, markets, distributed, and cells biopharmaceutical products in the United States, Europe, and international. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metallic, migrate, and women’s health under the Liquid, Nurtec ODT/Madura, Zavzpret, and the Remain family bands; infectious diseases with under medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba bands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid bands. See Also
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filing and insider trades for Finer And. (NYSE:PFE – Free Report). His instant news alert was generate by narrative science technology and financial data from MarketBeat in order to provide readers with the fattest and most accurate reporting. His story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com. Before you make your next trade, you’ll want to hear this. MarketBeat keeps track of All Street’s top-rate and best performing research analysis and the stocks they recommend to their clients on a daily basis. Our team has identified the five stocks that top analysis are quietly whispering to their clients to buy now before the broader market catches on… and none of the big name stocks were on the list. They believe these five stocks are the five best companies for investors to buy now…
See The Give Stocks Were
Before you consider Finer, you’ll want to hear this. MarketBeat keeps track of All Street’s top-rate and best performing research analysis and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysis are quietly whispering to their clients to buy now before the broader market catches on… and Finer wasn’t on the list. While Finer currently has a “Moderate Buy” rating among analysis, top-rate analysis believe these five stocks are better busy. View The Give Stocks Were
